The Role of IL5 in Epithelial Cell Integrity

Launched by JOHNS HOPKINS UNIVERSITY · May 30, 2023

Keywords

ClinConnect Summary

**Clinical Trial Summary: The Role of IL5 in Epithelial Cell Integrity**

This clinical trial is studying how a medication called mepolizumab can help people with chronic rhinosinusitis, particularly those who have nasal polyps. Chronic rhinosinusitis is a long-term condition that causes inflammation in the nasal passages, leading to symptoms like stuffy nose, facial pain, and loss of smell. Researchers want to understand how mepolizumab can reduce inflammation in the cells that line the nasal airways and help keep these cells strong and healthy.

To take part in this study, participants should be adults aged 18 and older who have had nasal inflammation for more than 12 weeks and experience symptoms like nasal congestion or facial pressure. They will need to have their condition confirmed through medical tests, such as a CT scan or an endoscopic exam. Participants will have the opportunity to learn more about their condition and potentially benefit from the treatment being tested. It’s important to note that certain individuals, such as children, pregnant women, and those with specific medical conditions, will not be eligible for this trial. If you or someone you know is interested, please reach out for more information about participating.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • (1) sinonasal inflammation for greater than 12 weeks which include at least 2 of the following symptoms: nasal obstruction/congestion, nasal discharge (anterior or posterior), facial pressure/pain, reduction of sense of smell.
• • (2) confirmation of the clinical symptoms by: (2a) CT scan evidence of paranasal sinus mucosal inflammation, and/or (2b) endoscopic exam evidence of purulence from the sinuses or ostiomeatal complex; and
• • (3) presence of nasal polyps seen on endoscopic exam or sinus CT scan.
• Exclusion Criteria:
• * 1. Children under the age of 18 will be excluded due to:
• • 1. possible confounding diagnosis of cystic fibrosis and other non-Type 2 inflammatory etiologies that commonly presents with nasal polyps in the pediatric population.
• • 2. lack of complete pneumatization of the majority of paranasal sinuses
• • 2. pregnant or lactating females,
• • 3. prisoners,
• • 4. mentally disabled
• • 5. persons unable to give informed consent will be contemplated for inclusion.
• • 6. disease secondary to a clearly defined anatomic process, such as facial trauma, and obstruction due to sinonasal neoplasm.
• • 7. exposure to oral or systemic IV glucocorticoids within 2 weeks of surgery
• • 8. exposure to immunomodulatory biologics will be excluded. These include, but are not limited to systemic treatment with biologics omalizumab, dupilumab, mepolizumab, benralizumab, reslizumab, or rituximab.